Loading
Latest filing published 10 Aug 2023 for Vincerx Pharma, Inc., €11k.
Across 2 buy signals with a settled T+90 return. Return basis: close on the day after publication.
Raquel E. Izumi is a declared insider of Vincerx Pharma, Inc., with filings sourced from SEC (Form 4). In total, 6 filings cover trades dated from 23 December 2020 to 10 August 2023.
The open-market record is one-sided, with 5 purchases worth €101k and not one sale. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. The rest of the record consists of 1 share grant. In 2023 alone, the filings show 2 purchases and no sales.
The median purchase comes to €11k. Clusters matter here: 3 out of 4 purchases overlapped with buying by a colleague within 30 days. Purchases made close together by different insiders form what is called a cluster.
On 10 August 2023 came the latest disclosure, an open-market purchase for €2,913 in Vincerx Pharma, Inc. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 2 days. For comparison, the SEC allows two business days to file a Form 4. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
4 of 4 declarations